Picture loading failed.

Pre-Made Lodelcizumab biosimilar, Whole mAb, Anti-PCSK9 Antibody: Anti-FH3/FHCL3/HCHOLA3/LDLCQ1/NARC-1/NARC1/PC9 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ligelizumab (QGE031) is a humanized monoclonal antibody (mAb) designed for the treatment of severe asthma and chronic spontaneous urticaria. his drug was developed by Novartis Pharma AG. As of 2018, ligelizumab is undergoing Phase III trials. It binds with high affinity to the Cε3 domain of IgE.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-318-1mg 1mg 3090
GMP-Bios-ab-318-10mg 10mg Inquiry
GMP-Bios-ab-318-100mg 100mg Inquiry
GMP-Bios-ab-318-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Lodelcizumab biosimilar, Whole mAb, Anti-PCSK9 Antibody: Anti-FH3/FHCL3/HCHOLA3/LDLCQ1/NARC-1/NARC1/PC9 therapeutic antibody
INN Name Lodelcizumab
TargetPCSK9
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2012
Year Recommended2013
CompaniesNovartis
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedHypercholesterolaemia
Development Techna